Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

@article{Jean2008EpidermalGF,
  title={Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.},
  author={Gary W. Jean and Sachin R. Shah},
  journal={Pharmacotherapy},
  year={2008},
  volume={28 6},
  pages={742-54}
}
Treatment of metastatic colorectal disease has evolved over the last decade. Two epidermal growth factor receptor (EGFR) monoclonal antibodies--cetuximab and panitumumab--have been developed in an effort to provide yet another therapeutic option. The EGFR is a transmembrane glycoprotein, expressed constitutively throughout the body and found on many epithelial tissues. The monoclonal antibodies bind to and inhibit the activation of the receptor in the body. This inhibition prevents tumor cell… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.

European journal of oncology nursing : the official journal of European Oncology Nursing Society • 2010
View 17 Excerpts
Highly Influenced

Adverse kidney effects of epidermal growth factor receptor inhibitors.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2017
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Cetuximab in the treatment of metastatic colorectal cancer.

Expert opinion on biological therapy • 2007
View 4 Excerpts
Highly Influenced

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2007
View 3 Excerpts
Highly Influenced

Phase II trial of FOLFOX6, becacizumab and cetuximab in patients with colorectal cancer [abstract

AJ Ocean, K O’Brien, J Lee
J Clin Oncol (2007 ASCO annual meeting proceedings) 2007;25(18S, June • 2007
View 1 Excerpt

Randomized phase III study of irinotecan and 5-FU/LA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial [abstract

E Van Cutsem, M Nowacki, I Lang
J Clin Oncol (2007 ASCO annual meeting proceedings) 2007;25(18S, June • 2007
View 1 Excerpt

Similar Papers

Loading similar papers…